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Background: Drug-resistant tuberculosis (TB) has emerged as a major challenge toward TB control and prevention.
In Lianyungang city, the extent and trend of drug resistant TB is not well known. The objective of the survey was to
assess drug resistance pattern of MTB and risk factors for drug resistant TB, including multidrug resistance
tuberculosis (MDR-TB) in this area.
Methods: We performed drug susceptibility testing on Mycobacterium tuberculosis (MTB) isolates with first- and
second-line anti-tuberculosis drugs of 1012 culture positive TB cases by using the proportion method, who were
consecutively enrolled from January 2011 to December 2012 in Lianyungang city, China. The patterns of drug
resistance in MTB were investigated and multiple logistic regression analysis was performed to assess the risk factors
for drug resistant TB.
Results: Among the 1012 strains tested, 308 (30.4%) strains were resistant to at least one first-line drug; the prevalence
of MDR-TB was 88 (8.7%), 5 (0.5%) strains were found to be extensively drug-resistant tuberculosis (XDR-TB). Female
gender was a risk factor for MDR-TB (adjusted odds ratio (aOR) 1.763, 95% CI (1.060-2.934). The aged 28–54 years was
significantly associated with the risk of MDR-TB with an aOR: 2.224, 95% CI (1.158-4.273) when compared with those
65 years or older. Patients with previous treatment history had a more than 7-fold increased risk of MDR-TB, compared
with those never previously treated.
Conclusions: The burden of drug resistant TB cases is sizeable, which highlights an urgent need to reinforce control,
detection and treatment strategies for drug resistant TB.
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Tuberculosis (TB) remains a major global health problem,
especially in high TB burden countries with large numbers
of TB patients and poorer sanitation. TB ranks as the sec-
ond leading cause of death among infectious diseases
worldwide, following only the human immunodeficiency
virus (HIV) [1]. According to the 2012 WHO global TB
report, China ranks as 2nd among the world’s 22 high bur-
den countries with a TB incidence around 1 million, and
the prevalence rate of TB was 104 per 100,000 patients
(95% confidence interval [95% CI] 91–119) and the* Correspondence: chencheng128@gmail.com; jsjkmck@163.com
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reproduction in any medium, provided the orincidence rate was 75 per 100,000 patients (95% CI 66–
85) in 2011 [1].
In a nationwide survey in China in 2007, the estimated
multidrug-resistant tuberculosis (MDR-TB) rate was
5.7% for new cases and 25.6% for previously treated
cases. Approximately 8% of the patients with MDR-TB
had extensively drug-resistant tuberculosis (XDR-TB)
[2]. However, information on the prevalence of MDR
and XDR-TB remains scant in the region. Drug-resistant
Mycobacterium tuberculosis(MTB) strains, MDR-TB and
XDR-TB strains may be the potential propellers for the
spread of TB, and through now we put great efforts in
TB control and treatment, the situation has not greatly
improved. Despite poor compliance to chemotherapy
duration, drug resistance of MTB would be another im-
portant factor for treatment failure among new TB casesThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rates [4].
Lianyungang city is located in the northeastern part of
China, and covers an area of 7.5 thousand square kilo-
meters with a population around 5 million in 2012. In-
formation on the prevalence of MDR-TB and XDR-TB
remains unknown in this region. Thus, we conducted
this study to assess drug resistance patterns of MTB on
first- and second-line anti-TB drugs in this region, and
evaluated related risk factors of drug resistance among
new and previously treated smear-positive TB patients.
Methods
Study population and isolates
In Lianyungang city, all newly registered patients with
sputum smear-positive pulmonary tuberculosis were col-
lected for strain identification and drug susceptibility
testing (DST). From January 2011 to December 2012, a
total of 1170 clinical isolates were collected from the
sputum samples of pulmonary tuberculosis patients. In
all surveys, each newly registered TB patient, positive on
sputum smear microscopy, was interviewed by the clin-
ician using the medical records to obtain the treatment
history. The medical records include personal informa-
tion, physical examinations, present illness, TB-related
complaints, previous medical history, family history and
PPD result. The treatment history of included cases was
classified by medical staff into new and previously
treated cases. New cases were defined as patients with
tuberculosis who have never been treated with anti-TB
drugs or received them for less than one month. Previ-
ously treated cases were defined as patients who have
been treated for tuberculosis for at least one month. The
definitions of new/previously treated cases referred to
the WHO guidelines [5].
Strain identification and drug susceptibility test
The sputum samples were cultured and isolated on
Lowenstein-Jensen (LJ) culture media which were pre-
pared by the Baso biotechnology Ltd (Zhuhai, China).
All the MTB isolates from positive culture were identi-
fied and subjected to DST. Identification of MTB was
done using the p-Nitrobenzoic acid (PNB) method and
the growth in LJ media containing PNB indicates that
the bacilli do not belong to the MTB complex. Species
other than MTB were excluded from the final analysis.
LJ media impregnated one anti-tuberculosis drug was
used for DST, and the corresponding drug concentra-
tions were as follows: 0.2 μg/ml for INH, 40 μg/ml for
RMP, 4 μg/ml for SM, 2 μg/ml for EMB, 30 μg/ml for
KM and 2 μg/ml for OFX. The LJ culture media were in-
cubated at 37°C.They were read twice at the first week
to detect contaminations and/or fast growth of atypical
mycobacteria and again every week thereafter for slowergrowing bacteria; if no bacteria grew by 6 weeks, the re-
sult was recorded as negative. Contaminated slant cul-
tures were discarded, and additional decontamination
and culture were undertaken using a stored portion of
the original sample. Resistance was expressed as the per-
centage of colonies that grew on the drug-containing
media compared to those on control media. The growth
of colonies in the drug containing plate was compared
to the control plate as a proportion. If the bacterial
growth on the media with the specific drug was ≥1%
compared to the control, the strain was declared resist-
ant to the specific drug; or it was defined as sensitive
when the growth rate was < 1% compared to the control.
Strains isolation, identification and DST were performed
at the fourth people’s hospital of Lianyungang city. Pro-
cedures for external quality assurance for smear and cul-
ture were based on WHO guidelines [1]. For internal
quality assurance of DST, a standard H37Rv strain was
included with each new batch of LJ media. External
quality control for culture and DST was conducted by
the provincial TB reference laboratory, which partici-
pates in the annual proficiency review of DST organized
by the Hong Kong Supranational Tuberculosis Reference
Laboratory and has passed each review since 2010.MDR and XDR
The following WHO-recommended definitions were used
for resistant cases:
MDR-TB was defined as TB with resistance to at least
INH and RMP. XDR-TB defined as MDR-TB plus resist-
ance to a fluoroquinolone and at least one second-line
injectable agent: amikacin, kanamycin and/or capreomy-
cin [5]. In our study the XDR-TB was defined as TB with
resistance to at least INH, RMP, KM and OFX.Statistical analysis
For comparison of categorical variables, significance test-
ing was done by χ2 test with by 2-sided Fisher exact test
as appropriate. Associations between selected factors
were estimated by computing odds ratios (ORs) and
their 95% confidence intervals (CIs) from an uncondi-
tional logistic regression model. The criterion for signifi-
cance was set at P < 0.05 based on a two-sided test.
Analyses were conducted with SPSS version 13.0 (SPSS
Inc., Chicago, IL, USA).Ethics statement
Informed written consent was obtained from all patients
and the study was approved by the Institutional Review
Board of Jiangsu Provincial Center for Disease Control
and Prevention. Ethics were respected throughout the
study period.
66 Culture negative cases 
11 contaminated cases  
1093 Culture confirmed cases 
1170 sputum smear positive 
1012 M.tuberculosis cases
816 New cases
196 Previously treated cases
59 Non-M.tuberculosis cases 
22 No Drug Susceptibility Test results  
Figure 1 Flow diagram of tuberculosis subjects included in
this study.
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Bacterial strains and patient characteristics
During the study period, 1170 sputum smear positive TB
cases were enrolled and 1093 clinical isolates reported a
culture positive MTB. Meanwhile, 66 cultured negativeTable 1 Characteristics of Patients with Culture Confirmed Pu
drug resistance, MDR-TB and XDR-TB













New Cases 816(80.6) 191(23.4)
Pre Treated Cases 196(19.4) 117(59.7)
Region
Rural areas 859(84.9) 258(30.0)




*Value by Fisher’s exact test.cases and 11 contaminated cases were excluded. Of the
1093 culture positive samples, 59 cultures were distin-
guished as Non-MTB (NTM). 22 samples failed for DST
assay were excluded. Thus, 1012 samples were included
in the final analysis (Figure 1). The age of the 1012 pa-
tients ranged from 14 to 90 years (mean ± SD), 49.8 ±
20.6, media 54), 748 (73.9%) of them were male and 264
(26.1%) were female. Of the 1012 case-patients included
in the study, 816 (80.6%) were new incidence and 196
(19.4%) were previously treated. 9 (0.9%) cases were mi-
grants.859 (84.9%) of the 1012 cases came from rural
areas (Table 1).
Prevalence of resistance to anti-tuberculosis drugs
This study observed most resistance of isoniazid 184
(18.2%) followed by streptomycin 141 (13.9%), rifampicin
114 (11.3%), ofloxacin 78 (7.7%), ethambutol 72 (7.1%),
and kanamycin 42 (4.2%). Among the new cases, drug
resistance was reported in 191(23.4%); INH resistance was
reported in 91 (11.2%), RMP resistance in 48 (5.9%), EMB
resistance in 30 (3.7%), SM resistance in 90 (11.0%), KM
resistance in 28 (3.4%), OFX resistance in 42 (5.1%),
Mono-resistance was found in 113 patients (13.8%), MDR
in 34 (4.2%) and XDR in 0 (0%). Among the 196 pre-
viously treated cases, drug resistance was reported in 117
(59.7%); INH resistance was reported in 93 (47.4%), RMPlmonary Tuberculosis: comparison of patients with any







































Table 2 Prevalence of anti-tuberculosis drug resistance
among M. tuberculosis isolates from new and previously
treated patients the results of drug susceptibility pattern

















Any resistance 191(23.4) 117(59.7) 308(30.4)
H 91(11.2) 93(47.4) 184(18.2)
R 48(5.9) 66(33.7) 114(11.3)
E 30(3.7) 42(21.4) 72(7.1)
S 90(11.0) 51(26.0) 141(13.9)
K 28(3.4) 14(7.1) 42(4.2)
O 42(5.1) 36(18.4) 78(7.7)
Mono-resistance 113(13.8) 22(11.2) 135(13.3)
H only 27(3.3) 8(4.1) 35(3.5)
R only 11(1.3) 3(1.5) 14(1.4)
E only 1(0.1) 0 1(0.1)
S only 42(5.1) 5(2.6) 47(4.6)
K only 18(2.2) 2(1.0) 20(2.0)
O only 14(1.7) 4(2.0) 18(1.8)
MDR-TB 34(4.2) 54(27.6) 88(8.7)
H + R 5(0.6) 13(6.6) 18(1.8)
H + R + E 2(0.2) 5(2.6) 7(0.7)
H + R + S 7(0.9) 10(5.1) 17(1.7)
H + R + K 0 0 0
H + R + O 2(0.2) 5(2.6) 7(0.7)
H + R + E + S 7(0.9) 4(2.0) 11(1.1)
H + R + E + K 0 0 0
H + R + E + O 4(0.5) 4(2.0) 8(0.8)
H + R + S + K 1(0.1) 1(0.5) 2(0.2)
H + R + S + O 2(0.2) 1(0.5) 3(0.3)
H + R + K + O 0 1(0.5) 1(0.1)
H + R + E + S + K 0 0 0
H + R + E + S + O 4(0.5) 6(3.1) 10(1.0)
H + R + E + K + O 0 1(0.5) 1(0.1)
H + R + S + K + O 0 1(0.5) 1(0.1)
H + R + E + S + K +O 0 2(1.0) 2(0.2)
XDR-TB 0 5(2.6) 5(0.5)
H: isoniazid, R: rifampicin, E: ethambutol, S: streptomycin, K: kanamycin and
O: ofloxacin. MDR-TB defined as resistance to at least H and R. XDR-TB defined
as resistance to at least H, R, K and O.
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SM resistance in 51 (26.0%), KM resistance in 14 (7.1%),
OFX resistance in 36 (18.4%), Mono-resistance was
present in 22 (11.2%), MDR in 54 (27.6%) and XDR in 5
(2.6%) patients, respectively (Table 2).
Factors associated with MDR-TB
The univariate analysis revealed a higher proportion of
female gender (cOR 1.704, 95% CI 1.077–2.697), individ-
uals aged 28–54 years (cOR 2.914, 95% CI 1.502–5.652),
and patients with previous TB treatment (cOR 8.746,
95% CI 5.495–13.922) amongst MDR-TB patients. The
final multivariable logistic regression model identified fe-
male gender (aOR 1.763, 95% CI 1.060–2.934), aged 28–
54 years (aOR 2.224, 95% CI 1.158–4.273) and previous
history of TB treatment (aOR 8.910, 95% CI 5.478–
14.492), to be associated with MDR-TB (Table 3).
Discussion
Information on anti-tuberculosis drug resistance levels is
an essential management tool for evaluating the per-
formance of national TB control programmers (NTPs).
Resistance in previously treated cases is an indicator of
current treatment practices in the community. Drug re-
sistance in new cases reflects transmission of disease
with resistant bacilli [6].
The prevalence of drug resistance in previously treated
cases was higher than new cases for each drug alone as
well as for all six drugs, as reported previously [2,7,8].
This suggests that retreatment is deficient and poses a
threat to continued transmission, which has not yet
manifested itself among new patients. The prevalence of
MDR-TB was 4.2% in new cases and 27.6% in previously
treated cases. As reported in a national survey of China,
the rates for MDR-TB in new and previously treated
cases were 5.7% and 25.6%, respectively [2]. The MDR-
TB prevalence among previously treated cases was mod-
estly higher than the national average, and among new
cases the rate was slightly lower. MDR-TB was observed
2.8% -14.7% of new cases and 9.7% -34.3% of previously
treated cases in China [2,9-12]. In Korea, resistance to at
least one first-line drug was identified in 11.7% of new
cases and 41.6% of previously treated cases. MDR-TB
was detected in 3.9% of new cases and 27.2% of previ-
ously treated cases. The proportion of XDR-TB among
MDR-TB patients was 16.7% (9/54) [13]. In Japan, The
prevalence of MDR in new and previously treated cases
was 0.7% and 9.8% respectively [14]. The overall MDR-
TB rate was 4.3%; 2.5% in new cases and 13.9% in previ-
ously treated cases in Pakistan [15]. MDR-TB was 0.2%
of new cases and 3.4% of previously treated cases in
Madagascar [16]. In Cambodia, no single MDR-TB was
found among the new cases and 3.1% in previously
treated cases [17]. In Yemen, The prevalence of MDR in
Table 3 Factors associated with multi-drug resistant tuberculosis
Variable Non-MDR, 924 MDR-TB, 88 Univariate Multivariate
n(%) n(%) cOR 95% CI p-Value aOR 95% CI p-Value
Female gender 232(25.1) 32(36.4) 1.704 1.077–2.697 0.022 1.763 1.060–2.934 0.029
Age 28–54 yr 219(23.7) 35(39.8) 2.914 1.502–5.652 0.002 2.224 1.158–4.273 0.016
migrant population 7(0.8) 2(2.3) 3.047 0.623–14.894 0.181* 4.385 0.807–23.821 0.087
Previous TB treatment 142(15.4) 54(61.4) 8.746 5.495–13.922 <0.001 8.910 5.478–14.492 <0.001
Rural areas 790(85.5) 69(78.4) 0.616 0.359–1.057 0.076 0.583 0.321–1.058 0.076
cOR, crude odds ratio; aOR, adjusted odds ratio, adjusted for sex, age, migrant population, treatment history and region. Values in boldface indicate a significant
(P<0.05) difference between Non-MDR and MDR-TB.
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spectively [18].
Compared MDR-TB patients, patients with XDR-TB
are more likely to die or have treatment failure [19,20].
The prevalence of XDR-TB among combined cases was
0.5%; it was 0% and 2.6% (5 cases) in new and previously
treated cases, respectively. XDR-TB was distributed
widely, albeit sporadically. This might imply that China’s
treatment strategy has improved, but that community
TB control is still insufficient [21]. The prevalence of
XDR-TB in new cases was slightly lower than the national
average (0.5%). However, XDR-TB prevalence among pre-
viously treated cases was a little higher than the national
average (2.1%) [2]. These findings points to the need for
interventions that will increase continuity of treatment
and reduce the rate of treatment default, especially among
patients treated within the hospital system [22].
As reported, 11% of new cases of tuberculosis and 16%
of previously treated cases were resistant to either INH
or RMP (but not both) before they received standard
first-line short-course treatment [2]. Resistance to these
first-line drugs were usually not detected because cultur-
ing and drug susceptibility testing are not routinely per-
formed at the local tuberculosis clinics. The use of
standard first-line drugs in the treatment of these pa-
tients may increase the risk of relapse, treatment failure
and acquired drug resistance [23-25].
Male or female TB patients could have different levels
of risk for drug resistance due to differences in access to
health-care services or exposure to other risk factors [5].
In the present study, the resistance rate to any drug was
similar in female and male, but females were more likely
to have MDR-TB than males, with an OR of 1.763 (95%
CI: 1.060-2.934), also reported in previous studies
[8,26-29]. The reasons for the association between fe-
male gender and MDR-TB are not well known. We
hypothesize that this association could be related to the
fact that women spend a long period of time caring for
men and others with MDR-TB both in households and
in healthcare settings in China where the majority of
health care workers are female [26,27]. TB diagnosis and
DST may be delayed among female patients, makingtreatment more difficult and inappropriate chemothera-
peutic regimens more likely [30,31]. It is also possible
that referring patients to the hospital may be different
for male and female patients and the providers may feel
reluctant to refer female patients with less complicated
infection to a tertiary care center [32]. Discovering gen-
der disparities associated with the risks of MDR-TB
could provide insight into the development of targeted
measures and improve access to health care and reduce
the risk of acquiring drug-resistance.
We also found that age was a significant factor in the
development of drug resistance. Resistance to any drug
and MDR was highest in those aged 28–54 years. The
association between age and the risk of MDR-TB is not
well established in the literature as different studies use
different cut-off points for age groups. However, it was
also reported that MDR-TB patients were more likely to
be younger than 65 years [33,34]. We assumed that age-
related difference in treatment adherence might be a
possible explanation, as patients at 28–54 years old were
often occupied by study, work or other activities on a
daily basis, in contrast with the more sedentary lifestyle
of elderly patients [34].
Many other risk factors for drug resistance tubercu-
losis and MDR-TB have been identified in recent stud-
ies: such as irregular treatment [35], urban residence
[12], non-permanent residents [34], urban migration
[12], lack of a sewage system in the home [35], frequent
travelers [34], alcoholism plus smoking, and lung cav-
ities [35]. Other important risk factors are associated
with the supply or quality of the drugs, the possible in-
adequate drug intake by patients, and others, such as
the lack of full supervision during the intensive phase of
treatment [36], poor NTPs [14,17], and the possible
high prevalence of highly virulent MDR-TB strains of
MTB [17,18,37].
There are several limitations of this survey. First, these
is potential misclassification of the new and previously
treated cases when some cases registered as new but
may actually have had TB treatment in the past. Second,
the burden of XDR-TB was underestimated because only
resistance to ofloxacin and kanamycin not resistance to
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tion was based on patient history of prior treatment for
TB and reviewing of medical records (which were not
available for all patients enrolled). Fourth, this survey
did not collect information on HIV infection status be-
cause patients with tuberculosis in China are not rou-
tinely tested for HIV.
Conclusions
This is the first prevalence survey on resistance to the
six major anti-tuberculosis drugs in Lianyungang city.
Our study showed that the high prevalence of drug re-
sistance is a major challenge for TB control. Patients
with previous treatment history and female gender are
risk factors for MDR-TB. Prevention and control of
drug-resistant TB should be emphasized by the revised
DOTS program through prompt case detection as well
as routine and quality-assured DST.
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